Veracyte

Veracyte

VCYT· Services· Fiscal year ends in December

CEO pay in FY2025Stock +6.3% in FY2025

Marc Stapley is the CEO of Veracyte and was paid $7.4M in FY2025 (Dec), up 9%.

Pay$100 in the stock at the end of FY21 → $102
CEO pay is from each Veracyte proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Marc StapleyFY2025
  2. 2John LeiteFY2025
  3. 3Rebecca ChambersFY2025
  4. 4Annie McGuireFY2025
  5. 5Phillip FebboFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Veracyte paid its 5 named executives $18.8M in total in FY2025 (Dec). CEO Marc Stapley was paid $7.4M of that.

Name
Marc StapleyChief Executive Officer
John LeiteGlobal Chief Commercial Officer
Rebecca ChambersChief Financial Officer
Annie McGuireGeneral Counsel and Head of Market Access
Phillip FebboChief Scientific Officer and Chief Medical Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers19

See all

The FY2025 (Dec) proxy of Veracyte names 19 peer companies for pay. Among Veracyte and these peers, CEO pay was 6th highest of 7 and total shareholder return was 3rd highest of 7.

6th highest of 7in Veracyte and its pay peers, FY2025 (Dec) by CEO pay:

$6.3M$15.0M

3rd highest of 7in Veracyte and its pay peers, FY2025 (Dec) by total shareholder return:

$12$230

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board4

See all
  • Marc StapleyDirector · 4 yr on the boardNot independent—Paid as an executive
  • Eliav BarrDirector · 3 yr on the boardIndependentRegulatory and Compliance—Paid as an executive
  • D. Brent ShaferDirector · 1 yr on the boardIndependentCompensation—Paid as an executive
  • Tom MillerDirector · 1 yr on the boardIndependentRegulatory and Compliance—Paid as an executive

The board of the latest proxy (FY2025).

Shared directors

Activity

  1. Pay
    Veracyte CFO pay fell 21% to $2.9M. The stock rose 6% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Veracyte Chief Scientific Officer and Chief Medical Officer pay fell 10% to $2.5M. The stock rose 6% in FY2025 (Dec).
    DEF 14A
  3. Board
    Tom Miller joined the board of Veracyte. Tom Miller sits on no other public board.
    3
  4. Pay
    Veracyte CFO pay rose 31% to $3.6M. The stock rose 44% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Veracyte Chief Scientific Officer and Chief Medical Officer pay fell 26% to $2.8M. The stock rose 44% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Veracyte CEO pay rose 46% to $7.2M. The stock rose 16% in FY2023 (Dec).
    DEF 14A
  7. Pay
    Veracyte Division head pay rose 61% to $3.1M. The stock rose 44% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Veracyte General counsel pay rose 25% to $3.1M. The stock rose 44% in FY2024 (Dec).
    DEF 14A
  9. Board
    Brent Shafer joined the board of Veracyte. Brent Shafer now sits on 3 public boards.
    3
  10. Pay
    Veracyte CFO pay fell 16% to $2.8M. The stock rose 16% in FY2023 (Dec).
    DEF 14A
  11. Pay
    Veracyte CEO pay rose 46% to $7.2M. The stock rose 16% in FY2023 (Dec).
    DEF 14A
  12. Pay
    Veracyte CEO pay fell 14% to $4.9M. The stock fell 42% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 22, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 28, 2025FY2024
Proxy statementDEF 14AApr 25, 2024FY2023
Annual report10-KFeb 29, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data